Supporting translational and clinical development of the lead IMT-009 program for lymphoma indications

In August 2021, LLS made an equity investment in Immunitas Therapeutics to provide "Support of Translational and Clinical Development of the Lead IMT-009 Program for Lymphoma Indications." IMT-009, a first-in-class NK and T cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. Immunitas is also advancing IMT-073, a dual-target NK and T cell modulator. The company was founded by Longwood Fund with leading scientists from Dana-Farber, MGH, the Broad, and MIT.